Occult axillary node metastases in breast cancer: Their detection and prognostic significance

British Journal of Cancer

Volumn 73, Issue 1, 1996, Pages 88-95

  McGuckin, M A ^a   Cummings, M C ^a   Walsh, M D ^a   Hohn, B G ^a   Bennett, I C ^a   Wright, R G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Breast cancer; Detection; Mucin; Occult metastases; Prognosis

Indexed keywords

CYTOKERATIN; EOSIN; HEMATOXYLIN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0030039429     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.16     Document Type: Article

References (28)

1. ACKERMAN LV AND ROSAI HJ. (1974). Surgical Pathology, 5th Edn. pp 895-896. CB Mosby: St Louis.
2. BYRNE J, MORGAN PG, ENGLAND S, CALLAGHAN J AND GIVEN HF. (1992). A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur. J. Cancer, 28, 658-660.
3. COTE RJ, ROSEN PP, LESSER ML, OLD LJ AND OSBORNE MP. (1991). Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Ontol., 9, 1749-1756.
4. DE MASCAREL I, BONICHON F, COINDRE JM AND TROJANI M. (1992). Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br. J. Cancer, 66, 523-527.
5. DEARNALEY DP, ORMEROD MG AND SLOANE JP. (1991). Micrometastases in breast cancer: long-term follow-up of the first patient cohort. Eur. J. Cancer, 27, 236-239.
6. ELSON CE, KUFE D AND JOHNSTON WW. (1993). Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. A study of 97 cases. Anal. Quant. Cytol. Histol., 15, 171-178.
7. ELSTON CW AND ELLIS IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19, 403-410.
8. FISHER B AND REDMOND C. (1992). Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Monogr. Nail Cancer Inst., 11, 105-116.
9. FRIEDMAN S, BERTIN F, MOURIESSE H, BENCHABAT A, GENIN J AND SARRAZIN D. (1988). Importance of tumor cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol., 27, 483-487.
10. GALEA MH, ATHANASSIOU E, BELL J, DILKS B, ROBERTSON JF, ELSTON CW, BLAMEY RW AND ELLIS IO. (1991). Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCRC-11. J. Pathol., 165, 221-227.
11. HAINSWORTH PJ, TJANDRA JJ, STILLWELL RG, MACHET D, HENDERSON MA, RENNIE GC, MCKENZIE IFC AND BENNETT RC. (1993). Detection and significance of occult metastases in node-negative breast cancer. Br. J. Surg., 80, 459-463.
12. HARRIS M, HOWELL A, CHRISSOHOU M, SWINDELL RIC, HUDSON M AND SELLWOOD RA. (1984). A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating ductal carcinoma of the breast. Br. J. Cancer, 50, 23-30.
13. INTERNATIONAL (LUDWIG) BREAST CANCER STUDY GROUP. (1990). Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet, 335, 1565-1568.
14. MCGUCKIN MA, WALSH MD, HOHN BG, WARD BG AND WRIGHT RG. (1995). Prognostic significance of MUC1 epithelial mucin expression in carcinoma of the breast. Hum. Pathol., 26, 432-439.
15. MCGUIRE WL, TANDON AK, ALLRED DC, CHAMNESS GC, RAVDIN PM AND CLARK GM. (1992). Treatment decisions in axillary node-negative breast cancer patients. Monogr. Natl Cancer Inst., 173-180.
16. NASSER IA, LEE AKC, BOSARI S, SAGANICH R, HEATLEY G AND SILVERMAN ML. (1993). Occult axillary lymph node metastases in node-negative breast carcinoma. Hum. Pathol., 24, 950-957.
17. NEMOTO T, VANA J, BEDWANI RN, BAKER HW, MCGREGOR FH AND MURPHY GP. (1980). Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer, 45, 2917-2924.
18. NIO Y, ZIGHELBOIM J, BEREK JS AND BONAVIDA B. (1990). Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nat. Immun. Cell Growth Regul., 9, 283-296.
19. NOGUCHI S, AIHARA T, NAKAMORI S, MOTOMURA K, INAJI H, IMAOKA S AND KOYAMA H. (1994). The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 74, 1595-1600.
20. RAYMOND WA AND LEONG AS-Y. (1989). Immunoperoxidase staining in the detection of lymph node metastases in stage 1 breast cancer. Pathology, 21, 11-15.
21. STEWART HJ. (1992). The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Monogr. Natl Cancer Inst., 11, 117-120.
22. TROJANI M, DE MASCAREL I, BONICHON F, COINDRE JM AND DELSOL G. (1987a). Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br. J. Cancer, 55, 303-306.
23. TROJANI M, DE MASCAREL I, COINDRE JM AND BONICHON F. (1987A). Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br. J. Cancer, 56, 838-839.
24. WELLS CA, HERYET A, BROCHIER J, GATTER KC AND MASON DY. (1984). The immunocytochemical detection of axillary micrometastases in breast cancer. Br. J. Cancer, 50, 193-197.
25. WILKINSON EJ AND HAUSE L. (1974). Probability in lymph node sectioning. Cancer. 33, 1269-1274.
26. WILKINSON EJ, HAUSE LL, HOFFMAN RG, KUZMA JF, ROTHWELL DJ, DONEGAN WL, CLOWRY LJ, ALMAGRO UA, CHOI H AND RIMM AA. (1982). Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol. Annu., 17, 67-91.
27. XING PX, TJANDRA JJ, STACKER SA, TEH JG, THOMPSON CH, MCLAUGHLIN PJ AND MCKENZIE IFC. (1989). Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol., 67, 183-195.
28. XING PX, REYNOLDS K, TJANDRA JJ, TANG XL AND MCKENZIE IF. (1990). Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res., 50, 89-96.